Siemens Healthineers MAGNETOM MRI Systems Advance with Imaginostics Quantitative Imaging Support Letter

Siemens Healthineers issues a Letter of Support to Imaginostics, signaling potential collaboration on quantitative MRI technologies for MAGNETOM systems. This development highlights growing interest in AI-driven imaging biomarkers that could transform diagnostic precision in clinical practice across Europe.

Siemens Healthineers has issued a Letter of Support to Imaginostics, fostering exploratory discussions on quantitative MRI technologies compatible with its MAGNETOM MRI systems. This move underscores the push toward AI-powered imaging biomarkers that deliver objective, reproducible clinical insights, positioning MAGNETOM systems at the forefront of precision diagnostics. For DACH investors, it signals Siemens Healthineers' strategic focus on innovative partnerships that enhance product competitiveness in a high-growth medical imaging market.

Updated: 21.03.2026

Dr. Elena Müller, Senior Editor for Medical Imaging and Health Tech, covering advancements in diagnostic technologies shaping European healthcare markets.

Letter of Support Marks Key Milestone for MAGNETOM Integration

The Letter of Support from Siemens Healthineers to Imaginostics, announced on March 20, 2026, initiates formal dialogue on potential technical and commercial pathways. Imaginostics' ImagiView and ImagiSight offerings aim to bring quantitative MRI capabilities to Siemens' MAGNETOM systems, enabling AI-driven digital twin insights for earlier disease detection.

This collaboration explores how quantitative imaging can make MRI scans more objective and actionable. MAGNETOM systems, known for their high-field strengths and advanced sequences, stand to benefit from these enhancements, potentially improving reproducibility in diagnostics for conditions like vascular diseases.

Dr. Codi Gharagouzloo, Imaginostics' Scientific Founder and CSO, emphasized the potential of quantitative MRI to shift healthcare from reactive to preventative models. The partnership evaluates compatibility within existing regulatory and development frameworks, with no binding agreements yet in place.

For MAGNETOM users in DACH hospitals, this signals upcoming software or hardware upgrades that could integrate biomarker analysis directly into workflows. Such advancements address longstanding challenges in qualitative MRI interpretation, where variability among radiologists can impact patient outcomes.

The timing aligns with rising demand for precision medicine in Europe, where MRI utilization grows at double-digit rates annually. Siemens Healthineers' proactive engagement positions its MAGNETOM lineup as a leader in this evolution.

Exploratory talks focus on technical feasibility, including how Imaginostics' AI algorithms process MAGNETOM data for vascular intelligence. This could enable lifetime health monitoring, a core goal of Imaginostics' Vascular Health for Life platform.

Quantitative MRI: Transforming MAGNETOM Capabilities

Quantitative MRI moves beyond visual assessment to deliver numerical biomarkers from scans. For MAGNETOM systems, this means transforming raw images into measurable data on tissue properties, blood flow, and disease progression.

Imaginostics' technology targets complex diseases by creating digital twins—virtual models of patient physiology derived from MRI. These models predict outcomes and personalize treatments, leveraging MAGNETOM's superior soft-tissue contrast.

In clinical settings, this enhances applications like oncology and cardiology, where precise quantification reduces false positives. DACH regions, with their advanced healthcare infrastructure, are prime markets for such innovations.

MAGNETOM systems already support advanced sequences for brain, prostate, and liver imaging. Integrating quantitative tools could standardize protocols across clinics, improving inter-site consistency vital for multicenter trials.

The support letter highlights potential for ImagiView in real-time analysis and ImagiSight for prognostic modeling. These tools aim to detect subtle changes invisible to traditional methods, extending MAGNETOM's utility in preventative care.

Engineers from both companies are reviewing data interoperability, ensuring seamless integration without overhauling existing MAGNETOM installations. This modular approach minimizes disruption for end-users.

Market analysts note that quantitative MRI adoption could boost scanner utilization by 20-30%, as clinicians order fewer repeat scans. For Siemens Healthineers, this translates to higher service revenues from software updates.

Commercial Implications in Growing Interventional Markets

The interventional radiology market, valued at USD 32.93 billion in 2026, grows at 7.6% CAGR to USD 63.66 billion by 2035. MRI modalities hold 10% share but lead in precision-guided procedures.

MAGNETOM systems fit perfectly into this ecosystem, supporting CT-guided and MRI-guided interventions. Collaborations like Siemens' past tie-up with Cook Medical in 2025 demonstrate a pattern of ecosystem building.

Quantitative enhancements could expand MAGNETOM's role in embolization, angioplasty, and biopsy procedures. AI fusion of MRI data with real-time fluoroscopy improves catheter navigation, reducing procedure times.

In DACH, where ambulatory surgical centers grow fastest at 6.8% CAGR, compact MAGNETOM variants offer ideal solutions. These centers prioritize minimally invasive tech, aligning with quantitative MRI's efficiency gains.

Biopsy devices market, projected to USD 5.08 billion by 2035, sees MRI-guided segments surging at 8.91% CAGR. MAGNETOM compatibility positions Siemens to capture share in prostate and breast diagnostics.

Helium shortages, as seen in global supply chains, underscore dry-cool tech in newer MAGNETOM models. This ensures operational reliability amid geopolitical tensions affecting cryogen supplies.

Commercial pathways under discussion include licensing Imaginostics software for MAGNETOM, joint development kits, or co-marketing. Any deal would require FDA and EU approvals, given Imaginostics' pre-clinical stage.

Investor Context: Siemens Healthineers Share Dynamics

Siemens Healthineers, listed under ISIN DE000SHL1006, benefits from imaging segment strength. The recent support letter reinforces R&D momentum without immediate financial commitments.

Share performance reflects broader medtech trends, with diagnostics driving margins. DACH investors value Siemens' European footprint and regulatory expertise in navigating MDR updates.

No direct stock reaction to the announcement, as it's exploratory. Long-term, successful integration could add recurring revenue from AI modules, bolstering growth forecasts.

IR pages highlight healthcare finance options, aiding MAGNETOM adoption in budget-constrained clinics. This service layer provides stability amid capital equipment cycles.

Technical Synergies with MAGNETOM Portfolio

MAGNETOM systems range from 1.5T to 7T, offering scalability for quantitative apps. BioMatrix technology already tunes sequences to patient physiology, priming for AI overlays.

Imaginostics' vascular focus complements MAGNETOM's cardiac and neuro strengths. Digital twin models could simulate interventions pre-procedure, enhancing safety.

In radiotherapy planning, MRInsights tools leverage MAGNETOM for soft-tissue delineation. Quantitative biomarkers would refine targeting, reducing margins and side effects.

DACH research hubs like German Cancer Research Center use MAGNETOM for trials. Partnership potential accelerates data validation for EU market entry.

AI integration addresses radiologist shortages, automating quantification. This frees experts for complex cases, optimizing throughput in high-volume centers.

Future updates may include cloud-based processing, allowing MAGNETOM users to access Imaginostics tools remotely. Scalability ensures broad adoption.

European Market Relevance for DACH Stakeholders

DACH hospitals lead MRI density in Europe, with Germany boasting over 40 scanners per million inhabitants. Quantitative upgrades future-proof investments.

Preventative paradigms gain traction under national health strategies. MAGNETOM's evolution supports earlier interventions, cutting long-term costs.

Competitors like Philips and GE push similar AI, but Siemens' open ecosystem invites partners like Imaginostics. This agility appeals to consortium buyers.

Regulatory alignment via joint efforts speeds CE marking. DACH regulators prioritize data security, met by Siemens' standards.

Training programs will disseminate skills, ensuring smooth rollout. Siemens' academy network in Munich and Vienna accelerates this.

Sustainability features in MAGNETOM, like low-energy modes, align with EU green goals. Quantitative efficiency further reduces scan times and power use.

Overall, the support letter catalyzes MAGNETOM's next phase, blending hardware excellence with software intelligence for superior patient care.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.